APA (7th ed.) Citation

Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., . . . Greenhalf, W. (2021). hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA. Cancers, 13(22), . https://doi.org/10.3390/cancers13225758

Chicago Style (17th ed.) Citation

Aughton, Karen, et al. "HENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA MRNA." Cancers 13, no. 22 (2021). https://doi.org/10.3390/cancers13225758.

MLA (9th ed.) Citation

Aughton, Karen, et al. "HENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA MRNA." Cancers, vol. 13, no. 22, 2021, https://doi.org/10.3390/cancers13225758.